By exploiting an integrated experimental platform based on patient-derived cancer stem cells, we identified a glioblastoma subset characterized by inheritable Erb-B2 Receptor Tyrosine Kinase 3 (ERBB3) overexpression, metabolic dependency on ERBB3 signaling, and liability to ERBB3 targeting. We provide insights on why some glioblastomas may rely on ERBB3 and how to recognize them.
ERBB3 as a therapeutic target in glioblastoma: overexpression can make the difference
De Bacco F.First
;Boccaccio C.
Last
2021-01-01
Abstract
By exploiting an integrated experimental platform based on patient-derived cancer stem cells, we identified a glioblastoma subset characterized by inheritable Erb-B2 Receptor Tyrosine Kinase 3 (ERBB3) overexpression, metabolic dependency on ERBB3 signaling, and liability to ERBB3 targeting. We provide insights on why some glioblastomas may rely on ERBB3 and how to recognize them.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
De Bacco & Boccaccio_Mol Cell Oncol_2022_PubMedC.pdf
Accesso aperto
Descrizione: Aticolo Principale
Tipo di file:
PDF EDITORIALE
Dimensione
438.78 kB
Formato
Adobe PDF
|
438.78 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
